Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
The purpose of the study is to comply with the Pediatric Investigation Plan requirements of Ipilimumab
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Exclusion Criteria:
M?nster, 48149, Germany
Df, Mexico City 06720, Mexico
Esplugues de Llobregat- Barcelona, 08950, Spain